Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SeaStar Medical Holding (ICU) EBITDA (2023 - 2025)

SeaStar Medical Holding (ICU) has disclosed EBITDA for 3 consecutive years, with -$3.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 19.64% year-over-year to -$3.6 million, compared with a TTM value of -$13.9 million through Sep 2025, up 13.03%, and an annual FY2024 reading of -$17.8 million, down 25.56% over the prior year.
  • EBITDA was -$3.6 million for Q3 2025 at SeaStar Medical Holding, down from -$1.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$1.8 million in Q2 2025 and bottomed at -$4.8 million in Q4 2024.
  • Average EBITDA over 3 years is -$3.7 million, with a median of -$3.8 million recorded in 2025.
  • The sharpest move saw EBITDA plummeted 62.31% in 2024, then skyrocketed 62.39% in 2025.
  • Year by year, EBITDA stood at -$2.9 million in 2023, then tumbled by 62.31% to -$4.8 million in 2024, then increased by 24.88% to -$3.6 million in 2025.
  • Business Quant data shows EBITDA for ICU at -$3.6 million in Q3 2025, -$1.8 million in Q2 2025, and -$3.8 million in Q1 2025.